Evidence map›Paper›PMID 30962337›Full record

ArticleAntimicrobial agents and chemotherapy2019

Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate.

Romain Carrez, Julien Brillault, Nicolas Grégoire, Isabelle Lamarche, Julian Laroche, William Couet, Sandrine Marchand

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Romain CarrezINSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
Julien BrillaultINSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
Nicolas GrégoireINSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
Isabelle LamarcheINSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
Julian LarocheINSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
William CouetINSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
Sandrine MarchandINSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France sandrine.marchand@univ-poitiers.fr.ORCID 0000-0001-5279-6678
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the pharmacokinetics of oseltamivir phosphate, a prodrug, and its active moiety in plasma and lung after its nebulization and intravenous administration in rats. Only 2% of prodrug was converted into active moiety presystematically, attesting to a low advantage of oseltamivir phosphate nebulization, suggesting that oseltamivir phosphate nebulization is not a good option to obtain a high exposure of the active moiety at the infection site within lung.

Indexed as

Administration, IntravenousAnimalsMaleOseltamivirPhosphatesProdrugsRatsRats, Sprague-DawleyOseltamiviroseltamivir carboxylatePhosphatesProdrugslungnebulizationoseltamivirpharmacokineticsprodrug

Identifiers

PMID30962337
PMCPMC6535510
OpenAlexW2938814414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.